Connect with us

Hi, what are you looking for?

Investing

Synairgen Pretax Loss Narrowed on Lower Expenses

By Najat Kantouar


Synairgen reported a narrowed pretax loss for the first half as research-and-development spending and manufacturing activities decreased.

The U.K. respiratory drug-discovery and biotechnology company said Thursday that pretax loss for the half year ended June 30 was 5.2 million pounds ($6.4 million) compared with GBP14.0 million for the same period a year earlier as expenditure on the Phase 3 Sprinter trial, substantially completed in 2022, fell and manufacturing activities reduced.

Administrative expenses were GBP2.1 million, with the reduction attributable to pre-commercialization activities incurred in 2022.

With no recurring revenue, the company’s available resources are sufficient to cover existing committed costs and the estimated costs of these activities until at least Sept. 30, 2024, Synairgen said.


Write to Najat Kantouar at [email protected]


Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

Content Sædvanligvis Populære Skuespil – troll hunters slot Get up wire €1000, 150 Free Spins De bedste free spins tilbud medmindre giroindbetalin Free Spins i...

Uncategorized

Posts Which Us online casino gets the greatest Issues the fresh Waking bonus offers? Totally free Fall Storms Maximum Gains for Aspects: The brand...

Uncategorized

Content Really does Bitstarz Gambling enterprise provide alive specialist games? How do i allege Bitcoin gambling establishment incentives? Betting Slotastic Again, the advantage and...

Uncategorized

Content Werden Casinos exklusive Umsatzbedingungen seriös? Sic funktioniert die Registrierung inoffizieller mitarbeiter besten Spielsaal unter einsatz von Bonus abzüglich Einzahlung Live Roulette Unser Live...